Clinical trial • Phase III • Psychiatry

Clinical trial in Major Depressive Disorder | Anhedonia

Phase III trial for Major Depressive Disorder | Anhedonia. 65 participants.

Overview

Trial Therapeutic Area
Psychiatry
Trial Disease
Major Depressive Disorder | Anhedonia
Trial Stage
Phase III

Key dates

Initial CTIS Submission Date
03-12-2024
First CTIS Authorization Date
14-04-2025

Trial design

Phase III trial across 1 site in Austria.

Target Sample Size
65

Eligibility

Recruits 65 No vulnerable populations selected; no consent or assent handling information provided..

Vulnerable Population
No vulnerable populations selected; no consent or assent handling information provided.

Recruitment

Planned Sample Size
65
Recruitment Window Months
38
Consent Approach
Informed consent process not specified in the provided data; no assent information provided; languages not stated.

Geography

Total Number Of Sites
1
Total Number Of Participants
65

Austria

Earliest CTIS Part Ii Submission Date
17-03-2025
Latest Decision Or Authorization Date
12-04-2026
Processing Time Days
391
Number Of Sites
1
Number Of Participants
65

Sites

Site Name
Medical University Of Vienna
Department Name
Department of Psychiatry and Psychotherapy, Division of General Psychiatry
Contact Person Name
Marie Spies
Contact Person Email
marie.spies@meduniwien.ac.at
Number Of Participants
65

Sponsor

Primary sponsor

Full Name
Medical University Of Vienna
Organisation Type
Educational Institution
Country Of Registered Address
Austria

Related trials

Other published trials that may interest you.